A Once-weekly, Repeated Dose, Placebo Controlled, Double Blind, Randomised Cross-over Trial Investigating Safety, Efficacy and Pharmacodynamics of FE 203799 in Patients With Short Bowel Syndrome With Intestinal Failure Requiring Parenteral Support Followed by an Additional Treatment Period in an Open Label Regimen.
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Apraglutide (Primary)
- Indications Short bowel syndrome
- Focus Adverse reactions
- Sponsors GLyPharma Therapeutic; Therachon
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week
- 05 Feb 2020 Status changed from recruiting to completed.
- 07 Jan 2020 According to a VectivBio media release, top-line results of this study is expected by the end of the first quarter of 2020.